Skip to main content

Table 2 Laboratory findings, corticosteroid usage, and hospital course in patients with SARS-CoV-2 pneumonia

From: Clinical features and predictors for patients with severe SARS-CoV-2 pneumonia at the start of the pandemic: a retrospective multicenter cohort study

  Non-severe (n = 35) Severe (n = 23) P value
Laboratory findings
 WBCs count, × 109 /L 5·1 (1·9) 5·9 (4·1) 0·3
 Lymphocyte count, × 109 /L 1·3 (0·4) 0·9 (0·4) 0·0
 C-reactive protein, mg/L 4·5 (0·6–10·9) 16·8 (3·9–55·8) 0·0
 D-dimer, mg/L 90·0 (45·5–180·0) 154·0 (113·3–470·5) 0·1
 ALT level, IU/L 20·9 (8·9) 28·3 (22·4) 0·1
 AST level, IU/L 24·0 (6·3) 31·0 (13·3) 0·0
Corticosteroid usage    0·0
 Yes 11 (31·4%) 14 (60·9%)  
 No 24 (68·6%) 9 (39·1%)  
Hospital course
 Time from onset of illness to antiviral treatment, days 3·0 (1·0–7·0) 4·0 (2·0–6·0) 0·6
 Clinical recovery time, days 8·3 (4·7) 12·9 (4·4) 0·0
 Time of virus nucleic acid turn to negative, days 11·8 (5·0) 15·7 (6·7) 0·0
 Hospitalization duration, days 14·4 (4·3) 20·7 (1·2) 0·0
  1. Abbreviations: WBCs, white blood cell counts; ALT, Alanine aminotransferase; AST, Aspartate Aminotransferase